These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32294361)

  • 1. PARP Inhibitors in Ovarian Cancer.
    da Costa A
    N Engl J Med; 2020 Apr; 382(16):1572-1573. PubMed ID: 32294361
    [No Abstract]   [Full Text] [Related]  

  • 2. PARP inhibitors and quality of life in ovarian cancer.
    Aoki D; Chiyoda T
    Lancet Oncol; 2018 Aug; 19(8):1012-1014. PubMed ID: 30026001
    [No Abstract]   [Full Text] [Related]  

  • 3. PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    Konstantinopoulos PA; Matulonis UA
    Clin Cancer Res; 2018 Sep; 24(17):4062-4065. PubMed ID: 29871906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP inhibitors for ovarian cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
    [No Abstract]   [Full Text] [Related]  

  • 5. Human mass balance study and metabolite profiling of
    van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PARP inhibitors in first-line of ovarian cancers].
    Rodrigues M
    Bull Cancer; 2020 Jan; 107(1):4-5. PubMed ID: 31928735
    [No Abstract]   [Full Text] [Related]  

  • 8. Niraparib Slows Ovarian Cancer Progression.
    Cancer Discov; 2016 Dec; 6(12):OF2. PubMed ID: 27810860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niraparib improves progression-free survival in ovarian cancer.
    Gourd E
    Lancet Oncol; 2019 Nov; 20(11):e615. PubMed ID: 31587884
    [No Abstract]   [Full Text] [Related]  

  • 10. Niraparib for the treatment of ovarian cancer.
    Essel KG; Moore KN
    Expert Rev Anticancer Ther; 2018 Aug; 18(8):727-733. PubMed ID: 29911447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):543-550. PubMed ID: 29620474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using PARP Inhibitors in Advanced Ovarian Cancer.
    O'Cearbhaill RE
    Oncology (Williston Park); 2018 Jul; 32(7):339-43. PubMed ID: 30080919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors: pitfalls and promises.
    Infante JR; Burris HA
    Lancet Oncol; 2013 Aug; 14(9):798-9. PubMed ID: 23810789
    [No Abstract]   [Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
    Liu CH; Chang Y; Wang PH
    Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
    [No Abstract]   [Full Text] [Related]  

  • 17. Nephrotoxicity Associated With Niraparib.
    Lazareth H; Delanoy N; Cohen R; Boissier E; Ayari H; Combe P; Crespel C; Mercadier-Riaz E; Karras A; Courbebaisse M; Thervet E; Pallet N
    Am J Kidney Dis; 2020 Dec; 76(6):898-900. PubMed ID: 32679152
    [No Abstract]   [Full Text] [Related]  

  • 18. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
    Li N; Wang Y; Deng W; Lin SH
    Anticancer Agents Med Chem; 2019; 19(2):206-212. PubMed ID: 30417796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.